Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) shares fell 6% during trading on Thursday. The stock traded as low as $1.0650 and last traded at $1.09. 240,975 shares changed hands during mid-day trading, an increase of 67% from the average daily volume of 143,940 shares. The stock had previously closed at $1.16.
Analyst Ratings Changes
Several research firms have weighed in on VANI. Wall Street Zen raised Vivani Medical from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vivani Medical in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $3.75.
Check Out Our Latest Stock Report on Vivani Medical
Vivani Medical Stock Down 6.0%
The business has a fifty day simple moving average of $1.28 and a 200-day simple moving average of $1.27. The firm has a market cap of $98.32 million, a P/E ratio of -3.11 and a beta of 2.35.
Vivani Medical (NASDAQ:VANI - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. On average, sell-side analysts anticipate that Vivani Medical, Inc. will post -0.30 EPS for the current fiscal year.
About Vivani Medical
(
Get Free Report)
Vivani Medical, Inc NASDAQ: VANI is a clinical-stage biopharmaceutical company developing long-acting, implantable drug-delivery systems for chronic diseases. Its proprietary NanoPortal technology is designed to deliver medicine continuously over extended periods, with the goal of reducing dosing frequency and potentially improving treatment adherence.
The company's development programs have focused primarily on metabolic conditions. Its lead candidates include NPM-115, an implantable formulation of exenatide being developed for chronic weight management, and NPM-119, an implantable exenatide product intended to treat type 2 diabetes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vivani Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.
While Vivani Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
